SpringerOpen Newsletter

Receive periodic news and updates relating to SpringerOpen.

Open Access Nano Express

Comparison of anti-angiogenic properties of pristine carbon nanoparticles

Mateusz Wierzbicki1, Ewa Sawosz1, Marta Grodzik1, Marta Prasek1, Slawomir Jaworski1 and André Chwalibog2*

Author affiliations

1 Division of Biotechnology and Biochemistry of Nutrition, Warsaw University of Life Sciences, Warsaw, Poland

2 Department of Veterinary Clinical and Animal Sciences, University of Copenhagen, Groennegaardsvej 3, Frederiksberg, Copenhagen, 1870, Denmark

For all author emails, please log on.

Citation and License

Nanoscale Research Letters 2013, 8:195  doi:10.1186/1556-276X-8-195

The electronic version of this article is the complete one and can be found online at: http://www.nanoscalereslett.com/content/8/1/195


Received:14 February 2013
Accepted:15 April 2013
Published:26 April 2013

© 2013 Wierzbicki et al.; licensee Springer.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Angiogenesis is vital for tumour formation, development and metastasis. Recent reports show that carbon nanomaterials inhibit various angiogenic signalling pathways and, therefore, can be potentially used in anti-angiogenic therapy. In the present study, we compared the effect of different carbon nanomaterials on blood vessel development. Diamond nanoparticles, graphite nanoparticles, graphene nanosheets, multi-wall nanotubes and C60 fullerenes were evaluated for their angiogenic activities using the in ovo chick embryo chorioallantoic membrane model. Diamond nanoparticles and multi-wall nanotubes showed the greatest anti-angiogenic properties. Interestingly, fullerene exhibited the opposite effect, increasing blood vessel development, while graphite nanoparticles and graphene had no effect. Subsequently, protein levels of pro-angiogenic growth factor receptors were analysed, showing that diamond nanoparticles decreased the expression of vascular endothelial growth factor receptor. These results provide new insights into the biological activity of carbon nanomaterials and emphasise the potential use of multi-wall nanotubes and diamond nanoparticles in anti-angiogenic tumour therapy.

Keywords:
Carbon nanoparticles; Angiogenesis; Graphene; Graphite; Fullerene; Diamond; Nanotubes

Background

Angiogenesis is the most common process of new blood vessel development. Growth of new vessels starts from pre-existing ones and consists of two main processes: sprouting (endothelial cell migration) and intussusception (splitting of vessels) [1,2]. The growth of blood vessels depends on a balance between angiogenesis-promoting and angiogenesis-inhibiting signalling molecules. Vascular network growth is an essential process, especially during embryonic development, tissue remodelling and regeneration. However, disorders in blood vessel development may foster diseases like chronic inflammatory disorders. Development of new vessels is also essential for the growth and metastasis of tumours, in which pro-angiogenic molecules like vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) play critical roles. Binding of FGF and especially VEGF, which is considered a major molecule controlling blood vessel morphogenesis, to their tyrosine kinase receptors activates multiple downstream molecules involved in different signalling pathways that lead to increased vascular permeability, cell migration and proliferation [3]. The VEGF receptor KDR (also called Flk-1) and the FGF receptor FGFR are responsible for regulating angiogenesis (for reviews, see [4,5]).

Therapeutic anti-angiogenic compounds have been extensively studied for anti-tumour therapy. VEGF inhibitors have been approved for clinical use in cancer diseases. However, anti-VEGF therapy is effective only in particular cases and can lead to serious toxicity [6,7]. Angiogenesis is a complex process regulated by several regulators. Inhibiting only the VEGF signalling pathway seems to be insufficient. Hence, therapeutic agents affecting tumour cells without harming healthy cells are necessary to optimise cancer treatments. Carbon nanomaterials can be used as low-toxicity inhibitors of tumour angiogenesis. It has been demonstrated that nanoparticles of diamond, graphite, graphene, nanotubes and fullerenes display low toxicity [8-11]. Recently, we showed that diamond nanoparticles and microwave-radiofrequency carbon decreased the vascular network in glioblastoma tumours and mRNA levels of VEGFA and bFGF [12]. Furthermore, because of their high surface-to-volume ratio, carbon nanomaterials cause high biological activity and enable easy surface modification [13,14]. We hypothesised that pristine carbon nanoparticles can affect VEGF and bFGF receptors and inhibit tumour angiogenesis, but the effectiveness of anti-angiogenic activity can vary between different carbon nanostructures. Consequently, the objective of this study was to explore the anti-angiogenic properties of different carbon nanomaterials to find the most efficient for anti-angiogenic tumour therapy.

Methods

Nanomaterials

In the present study, we used in ovo chicken embryo chorioallantoic membranes (CAM) to compare the anti-angiogenic properties of pristine carbon nanomaterials: diamond nanoparticles (ND), graphite nanoparticles (NG), graphene nanosheets (GNS), multi-wall nanotubes (MWNT) and C60 fullerenes (C60). The physical characteristics of the nanoparticles are given in Table 1. ND and NG are spherical nanoparticles, produced by the detonation method with size ranging from 3 to 4 nm. C60 is a spherical nanoparticle that in water solvent aggregates into particles with a mean size of approximately 50 nm. GNS and MWNT are nanomaterials having diameters of 6 to 8 nm and 8 nm, and length of approximately 15 μm and 5 to 20 μm, respectively. Purity and specific surface area (except C60) were provided by the manufacturers. C60 was obtained from SES Research (Houston, TX, USA), and all other materials were from Skyspring Nanomaterials (Houston, TX, USA). The nanomaterials were dispersed in demineralised water using sonication. New solutions were made a day before each repetition. The shape and size of the nanomaterials were visualised using a JEM-2000EX transmission electron microscope (JEOL Ltd., Tokyo, Japan) at 200 kV (Figure 1). Zeta potential measurements were carried out on a Zetasizer Nano-ZS90 (Malvern, Worcestershire, UK) at 25°C. Measurements were conducted using Smoluchowski approximation, which is rigorously valid only for spherical particles. Therefore, the zeta potential of non-spherical nanomaterials may be overestimated by up to 20% [15].

Table 1. Comparison of the physical characteristics of the carbon nanoparticles

thumbnailFigure 1. Transmission electron microscopic images of carbon nanomaterials. (A) GNS, (B) NG, (C) ND, (D) C60 and (E) MWNT.

CAM assay

CAM implants were made from sterile Waterman filter paper with a diameter of 10 mm. Water (control) or hydrocolloids of nanoparticles of a concentration of 500 mg/L were added to the implants (final amount of nanoparticles on the implant was 0.01 mg). The implants were pre-treated with 3 mg/mL of hydrocortisone sodium succinate (Sigma, St. Louis, MO, USA) and air dried under sterile conditions. Fertilised eggs from Ross line 308 hens were obtained from a certified hatchery and kept for 4 days at 12°C. The eggs were cleaned, sterilised with UVC light and divided into six groups (6 × 20 eggs). Embryos were incubated at standard conditions (temperature 37°C, humidity 60% and turned once per hour). Embryonic day 0 (E0) started when the eggs were placed into the incubator. At day E6, small holes (1 cm2) were made on the shell above air space, the inner membrane was gently stripped off, and the implants were placed on CAM. The chicken embryos were incubated until day 7 of embryonic development, when implants with CAM were prefixed with 1.5 mL of 4% paraformaldehyde. After 30 min of incubation at 4°C, CAM with implants were cut out and fixed at 4°C in 4% paraformaldehyde for 60 min (total fixation time, 90 min). After fixation, the implants were gently stripped off. All measurements were repeated three times minimum.

CAM tissue angiogenesis analysis

The methodology of quantifying blood vessel development was based on [17] and [18], validated and used for this investigation. CAM tissues from implants were investigated with a stereomicroscope under a 12.5-fold magnification (SZX10, CellD software version 3.1, Olympus Corporation, Tokyo, Japan). Photos were analysed with CellSens Dimension Desktop version 1.3 (Olympus Corporation). The level of angiogenesis in eight CAM tissues from each group was determined by calculating the vessel area, length and number of branch points on three square areas of dimensions 2.5 × 2.5 mm (total area, 18.75 mm2 out of 78.5 mm2). CAM tissue areas were selected semi-randomly so that the vessels with a diameter greater than 200 μm were not assessed. Vessel area, length and number of branch points were calculated separately for vessels with a diameter smaller than 100 μm and those between 100 and 200 μm. To calculate the vessel area, the intensity differences between vessels and background were increased. Local contrast of images was strengthened by increasing the intensity by 20 and brightness by 300 (kernel radius, 128). The threshold was set at intensity volumes between 0 and 256 for shades of red, 0 and 256 for green, and 0 and 145 for blue (Figure 2).

thumbnailFigure 2. CAM assay for determining total area of vessels with CellSens Dimension Desktop version 1.3. (A) CAM square area of dimensions 2.5 × 2.5 mm and (B) image with a strengthened local contrast of images by increasing intensity and brightness. (C) For total area calculation, the threshold was set at intensity volumes between 0 and 256 for the shades of red, 0 and 256 for green, 0 and 145 and for blue.

CAM tissue morphological analysis

CAM implant morphology and development of capillary vessels were determined with the stereomicroscope described above. CAM cross sections were made with a cryostat (CM 1900, Leica, Wetzlar, Germany). Blocks were cut into 5-μm-thick sections and observed under a light microscope (DM 750, Leica).

Immunoblotting

Protein levels of CAM KDR and FGFR were examined by Western blot analysis. Protein extracts were prepared with TissueLyser LT (Qiagen, Hilden, Germany) using ice-cold RIPA buffer (150 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS, 50 mM Tris, pH 7.4) with protease and phosphatase inhibitors (Sigma). The protein concentration was determined by the Total Protein Kit, Micro Lowry, Peterson's Modification (Sigma). An equal volume (50 mg) of samples was denatured by the addition of sample buffer (Bio-Rad Laboratories, Munich, Germany) and boiled for 4 min. Proteins were resolved under reductive conditions with SDS-PAGE and transferred onto PVDF membrane (Life Technologies, Gaithersburg, MD, USA). Protein bands were visualised with the GelDoc scanner (Bio-Rad Laboratories), using the fluorescent method of the WesternDot Kit (Life Technologies) and the primary antibodies bGFR (cat. no. F4305-08, USBiological, Swampscott, MA, USA), KDR (cat. no. SAB4300356, Sigma) and GAPDH (cat. no. NB300-327, Novus Biologicals, Cambridge, UK) as loading control (dilutions recommended by the producers). Protein bands were characterised using the Quantity One 1-D analysis software (Bio-Rad Laboratories).

Statistical analysis

A one-way analysis of variance with the Bonferroni post hoc test was used for multiple comparisons. Differences at P < 0.05 were considered significant. Results are shown as means and standard errors.

Results

We compared the influence of different carbon nanoparticles on the development of blood vessels, using the chicken embryo CAM implantation method as a model for angiogenesis [19]. The experiments were repeated three times minimum, and all repetitions gave equivalent results. Changes in the development of blood vessels after nanoparticle treatments were observed by measuring changes in the mean vessel area, vessel length and the number of branch points. These parameters were investigated in vessels at two development states: older with a diameter between 100 and 200 μm and newly developed with a diameter smaller than 100 μm. The area of blood vessels with a diameter between 100 and 200 μm was the largest in the C60-treated group. However, these changes were not statistically significant (Table 2). Vessel length decreased after MWNT and ND treatment. Both nanoparticles caused a comparable decrease in blood vessel length. Of all the investigated nanoparticles, only ND significantly decreased the number of branch points. Assessment of the development of vessels with a diameter smaller than 100 μm showed different results. The area of newly developed vessels treated with ND was significantly smaller, compared to the other groups (Table 3). Both ND and MWNT decreased vessel length and the number of branch points, but ND had a significantly stronger effect. Furthermore, capillary vessels of MWNT- and especially ND-treated implants were poorly developed (Figure 3). Vessel branching was also affected by C60, resulting in an increased number of vessel branch points. NG and GNS showed no effect on the examined parameters in both older and newly formed vessels.

Table 2. Comparison of angiogenesis parameters of vessels with a diameter between 100 and 200 μm

Table 3. Comparison of angiogenesis parameters of vessels with a diameter less than 100 μm

thumbnailFigure 3. CAM vessel morphology in response to treatment with carbon nanoparticles. (A) Control, (B) GNS, (C) NG, (D) ND, (E) C60 and (F) MWNT. Scale bar, 500 μm.

To confirm whether nanoparticles affected CAM morphology, we investigated CAM cross sections (Figure 4). In the control group, the mean CAM thickness varied between 250 and 380 μm. In the ND- and MWNT-treated groups, the mean thickness varied between 80 and 200 μm and 90 and 260 μm, respectively. The other tested nanoparticles did not affect CAM morphology.

thumbnailFigure 4. Cross sections of CAM tissue treated with carbon nanoparticles. (A) Control, (B) GNS, (C) NG, (D) ND, (E) C60 and (F) MWNT. Scale bar, 100 μm.

Expression of KDR correlated with the pro- and anti-angiogenic properties of C60 and ND, but not MWNT (Table 4, Figure 5). Compared to the control group, ND reduced the expression of KDR by 38%. Fullerenes increased the KDR protein level by 30%. The other tested nanoparticles did not significantly alter the protein levels of KDR. FGFR protein amounts were not affected by all the tested carbon nanoparticles.

Table 4. Relative percentage of KDR and FGFR protein levels calculated with GAPDH as the loading control

thumbnailFigure 5. Representative immunoblot of KDR and FGFR CAM protein expression levels examined by Western blotting. GNS, graphene nanosheet; NG, graphite nanoparticle; ND, diamond nanoparticle; C60, fullerene C60; MWNT, multi-wall nanotube; KDR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Discussion

In this work, we compared the anti-angiogenic properties of carbon-based nanomaterials. The measurements were performed using the well-established chicken embryo CAM model [17,19]. CAM growth is essential for embryo development and is almost complete by 1 to 14 days of embryogenesis [20]. Blood vessel development was examined in the phase of the most intensive vessel growth, which was on day 7 of chicken embryo development [21].

The present results are consistent with our previous research, demonstrating that ND and microwave-radiofrequency carbon allotrope decreased the vascular network in glioblastoma tumour and, consequently, their volume and weight. Moreover, diamond nanoparticles decreased the mRNA level of the main pro-angiogenic factors VEGFA and bFGF [12]. ND also affected the transcription level of the human stress-responsive genes of cells exposed to stress (heat shock, cytotoxic and oxidative stress). It has been demonstrated that although ND did not show toxic effects on leukaemia cell line HL-60, it up-regulates the expression of the gene SOD1, responsible for the defence mechanism against reactive oxygen species, and down-regulates the genes JUN, GADD45A and FRAP1, responsible for protection against genotoxic and cellular stress [22]. Moreover, the anti-angiogenic activity of nanoparticles has been related to their inhibitory effects on pro-angiogenic factors. Gold nanoparticles specifically bind to VEGFA and bFGF and inhibit their interaction with cell membrane receptors [23,24].

Among all the tested nanoparticles, only MWNT and more significantly ND showed anti-angiogenic activity. Nanomaterials with graphite structure (NG and GNS) did not alter blood vessel development. There are only a few studies on the biological activity of GNS. Wang et al. [25] showed that GNS oxide exhibited low toxicity in mice and human fibroblast cells. Furthermore, GNS displayed low cytotoxicity in erythrocytes and fibroblasts [26], which together with our results suggests that GNS is highly biocompatible with the vascular system. Similarly, NG had no effect on CAM angiogenesis, although they have the same shape and similar size and are produced in the same way (but under different conditions) as ND [27], which had the strongest anti-angiogenic activity (Table 1). The strongest inhibition of vessel growth by ND may be linked to the inhibition of VEGF receptor (KDR) expression. VEGF is a major pro-angiogenic factor essential for the development of the blood vessel network. It is controlled by the release of growth factors dependent on the oxygen level, with HIF-1 being one of the most important [3]. Hypoxia leads to the up-regulation of VEGF and, thus, the formation of new blood vessels, which consequently normalises the oxygen status. In tumours, high activity and fast divisions of tumour cells lead to oxygen deficiency that enhances vessel growth. KDR is also regulated by various signalling molecules in response to changes in oxygen concentration [28,29]. Hypoxia leads to KDR up-regulation and activation of the angiogenic signalling cascade [30,31]. Down-regulation of KDR by ND may decrease hypoxia-mediated angiogenesis and exert efficient and long-lasting anti-angiogenic effects. Moreover, chronic hypoxia can lead to further down-regulation of KDR [32]. MWNT showed anti-angiogenic activity, inhibiting the branching of vessels with a diameter smaller than 100 μm. This indicates that MWNT inhibits the development of smaller/younger vessels only. Our report is consistent with the results of another study showing that pristine MWNT displayed an anti-angiogenic effect on an in vivo VEGFA/bFGF-induced model [33] and in in vitro HUVEC tubule formation assays [34]. However, doxorubicin conjugated with single-wall nanotubes had the opposite effects [35].

As expected, nanoparticles had less impact on the development of older vessels. Only ND, which exerted the strongest anti-angiogenic properties, induced a significant decrease in vessel length and the number of branch points. However, ND did not change the area of older vessels (100 to 200 μm). Reduced length and branching without significant changes in vessel area suggest that ND can inhibit the development of vessels with dimensions that slightly exceed 100 μm and smaller. The present results give new insights into the bioactive properties of ND and clearly show that this carbon nanoparticle can be considered for use in low-toxicity anti-angiogenic therapy.

Interestingly, our results demonstrated pro-angiogenic activity of pristine C60, which increased the number of branch points and vessel length. Fullerene C60 has been used to inhibit cancer growth [36] and is used as photosensitisers in photodynamic therapy [37]. However, Zogovic et al. [38] studied the effect of nanocrystaline fullerene on melanoma tumour and showed that fullerene, probably by immunosuppression, had tumour-promoting activity and increased the production of nitric oxide (NO), which can promote angiogenesis [39]. Furthermore, other reactive oxygen species can also induce angiogenesis [40]. The ability of C60 to generate reactive oxygen species has been previously demonstrated [41,42]. NO promotes angiogenesis by up-regulating the expression of the VEGFA receptor [43], which is consistent with our report. This appears to be the most probable mechanism underlying fullerene pro-angiogenic effects and may only be specific for pristine nanoparticles. Hydroxylated C60 has been shown to protect cells in vitro form oxidative stress, while pristine nanoparticles show pro-oxidant capacity [44,45]. Moreover, C60 modified with multihydroxylated metal can simultaneously down-regulate more than ten angiogenic factors and significantly decrease the capillary vessels of tumours (average size 1.2 cm in diameter) [46]. Murugesan et al. [33] demonstrated that pristine MWNT and C60 inhibited the angiogenesis induced by exogenous VEGFA or bFGF. Our results indicated that C60 had the opposite effect on vessels not stimulated by exogenous pro-angiogenic factors. This suggests that C60 can have both anti- and pro-angiogenic activity depending on the physiological state of blood vessels.

Conclusions

We compared the anti-angiogenic properties of pristine carbon nanomaterials. According to our results, the carbon nanomaterials showing the most anti-angiogenic to pro-angiogenic properties were as follows: diamond nanoparticles (anti-angiogenic) - multi-wall nanotubes - graphite nanoparticles (no activity) - graphene nanosheets - fullerene C60 (pro-angiogenic). Only diamond nanoparticles, multi-wall nanotubes and fullerenes showed statistically significant results. Nanoparticles showing anti-angiogenic effects also changed the morphology of CAM by decreasing its thickness. Diamond nanoparticles and fullerene changed the expression level of KDR, but not FGFR, thereby affecting the angiogenic potential of CAM. Multi-wall nanotubes and especially diamond nanoparticle can be considered potential inhibitors of blood vessel growth in anti-angiogenic tumour therapy.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MW prepared the angiogenesis assay, carried out the experimental analysis and drafted the manuscript. MW and MG performed the in ovo experiments. SJ made the TEM observations. MP carried out the immunobloting experiments. AC and ES supervised the work and finalized the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the following grants: NCN 2011/03/N/NZ9/04290 and NCN NN311540840. The report is a part of the doctoral thesis of Mateusz Wierzbicki.

References

  1. Adams RH, Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis.

    Nat Rev Mol Cell Biol 2007, 8:464-478. PubMed Abstract | Publisher Full Text OpenURL

  2. Kurz H, Burri PH, Djonov VG: Angiogenesis and vascular remodeling by intussusception: from form to function.

    News Physiol Sci 2003, 18:65-70. PubMed Abstract | Publisher Full Text OpenURL

  3. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors.

    Nat Med 2003, 9:669-676. PubMed Abstract | Publisher Full Text OpenURL

  4. Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.

    J Biochem Mol Biol 2006, 39:469-478. PubMed Abstract | Publisher Full Text OpenURL

  5. Cross M, Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.

    Trends Pharmacol Sci 2001, 22:201-207. PubMed Abstract | Publisher Full Text OpenURL

  6. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

    Nat Clin Pract Oncol 2006, 3:24-40. PubMed Abstract | Publisher Full Text OpenURL

  7. Carmeliet P, Jain RK: Molecular mechanism and clinical applications of angiogenesis.

    Nature 2011, 473:298-307. PubMed Abstract | Publisher Full Text OpenURL

  8. Sayes CM, Fortner JD, Guo W, Lyon D, Boyd AM, Ausman KD, Tao YJ, Sitharaman B, Wilson LJ, Hughes JB, West JL, Colvin VL: The differential cytotoxicity of water-soluble fullerenes.

    Nano Lett 2004, 4:1881-1887. Publisher Full Text OpenURL

  9. Dumortier H, Lacotte S, Pastorin G, Marega R, Wu W, Bonifazi D, Briand JP, Prato M, Muller S, Bianco A: Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells.

    Nano Lett 2006, 6:1522-1528. PubMed Abstract | Publisher Full Text OpenURL

  10. Schrand AM, Dai L, Schlager JJ, Hussain SM, Osawa E: Differential biocompatibility of carbon nanotubes and nanodiamonds.

    Diam Relat Mater 2007, 16:2118-2123. Publisher Full Text OpenURL

  11. Liu KK, Cheng CL, Chang CC, Chao JI: Biocompatible and detectable carboxylated nanodiamond on human cell.

    Nanotechnology 2007, 18:325102. Publisher Full Text OpenURL

  12. Grodzik M, Sawosz E, Wierzbicki M, Orlowski P, Hotowy A, Niemiec T, Szmidt M, Mitura K, Chwalibog A: Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo.

    Int J Nanomedicine 2011, 6:3041-3048. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  13. Holt KB, Ziegler C, Caruana DJ, Zang J, Millán-Barrios EJ, Hu J, Foord JS: Redox properties of undoped 5 nm diamond nanoparticles.

    Phys Chem Chem Phys 2008, 10:303-310. PubMed Abstract | Publisher Full Text OpenURL

  14. Krueger A, Stegk J, Liang Y, Lu L, Jarre G: Biotinylated nanodiamond: simple and efficient functionalization of detonation diamond.

    Langmuir 2008, 24:4200-4204. PubMed Abstract | Publisher Full Text OpenURL

  15. O'brien RW, Ward DN: Electrophoresis of a spheroid with a thin double layer.

    J Colloid Interface Sci 1988, 121:402-413. Publisher Full Text OpenURL

  16. Cheng XK, Kan AT, Tomson MB: Naphthalene adsorption and desorption from aqueous C60 fullerene.

    J Chem Eng Data 2004, 49:675-683. Publisher Full Text OpenURL

  17. Brooks PC, Montgomery AM, Cheresh DA: Use of the 10-day-old chick embryo model for studying angiogenesis.

    Methods Mol Biol 1999, 129:257-269. PubMed Abstract | Publisher Full Text OpenURL

  18. Blacher S, Devy L, Hlushchuk R, Larger E, Lamandé N, Burri P, Corvol P, Djonov V, Foidart JM, Noël A: Quantification of angiogenesis in the chicken chorioallantoic membrane (CAM).

    Image Analysis & Stereology 2005, 24:169-180. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  19. Ribatti D, Vacca A, Roncali L, Dammacco F: The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis.

    Int J Dev Biol 1996, 40:1189-1197. PubMed Abstract | Publisher Full Text OpenURL

  20. Flamme I: Is extraembryonic angiogenesis in the chick embryo controlled by the endoderm? A morphology study.

    Anat Embryol (Berl) 1989, 180:259-272. Publisher Full Text OpenURL

  21. Javerzat S, Franco M, Herbert J, Platonova N, Peille AL, Pantesco V, De Vos J, Assou S, Bicknell R, Bikfalvi A, Hagedorn M: Correlating global gene regulation to angiogenesis in the developing chick extra-embryonic vascular system.

    PLoS One 2009, 4:e7856. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  22. Bakowicz-Mitura K, Bartosz G, Mitura S: Influence of diamond powder particles on human gene expression.

    Surf Coatings Technol 2007, 201:6131-6135. Publisher Full Text OpenURL

  23. Bhattacharya E, Mukherjee P, Xiong Z, Atala A, Soker S, Mukhopadhyay D: Gold nanoparticles inhibit VEGF165-induced proliferation of HUVEC cells.

    Nano Lett 2004, 4:2479-2481. Publisher Full Text OpenURL

  24. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S: Antiangiogenic properties of gold nanoparticles.

    Clin Cancer Res 2005, 11:3530-3534. PubMed Abstract | Publisher Full Text OpenURL

  25. Wang K, Ruan J, Song H, Zhang J, Wo Y, Guo S, Cui D: Biocompatibility of graphene oxide.

    Nanoscale Res Lett 2011, 6:8. OpenURL

  26. Liao KH, Lin Y, Macosko CW, Haynes CL: Cytotoxicity of graphene oxide and graphene in human erythrocytes and skin fibroblasts.

    ACS Appl Mater Interfaces 2011, 3:2607-2615. PubMed Abstract | Publisher Full Text OpenURL

  27. Jiang Q, Li JC, Wilde G: The size dependence of the diamond-graphite transition.

    J Phys Condens Matter 2000, 12:5623. Publisher Full Text OpenURL

  28. Wang J, Morita I, Onodera M, Murota SI: Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide.

    J Cell Physiol 2002, 190:238-250. PubMed Abstract | Publisher Full Text OpenURL

  29. Duval M, Bédard-Goulet S, Delisle C, Gratton JP: Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells.

    J Biol Chem 2003, 278:20091-20097. PubMed Abstract | Publisher Full Text OpenURL

  30. Waltenberger J, Mayr U, Pentz S, Hombach V: Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia.

    Circulation 1996, 94:1647-1654. PubMed Abstract | Publisher Full Text OpenURL

  31. Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP: Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin.

    J Invest Dermatol 1997, 108:263-268. PubMed Abstract | Publisher Full Text OpenURL

  32. Olszewska-Pazdrak B, Hein TW, Olszewska P, Carney DH: Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells.

    Am J Physiol Cell Physiol 2009, 296:C1162-C1170. PubMed Abstract | Publisher Full Text OpenURL

  33. Murugesan S, Mousa SA, O'connor LJ, Lincoln DW 2nd, Linhardt RJ: Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis.

    FEBS Lett 2007, 581:1157-1160. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  34. Walker VG, Li Z, Hulderman T, Schwegler-Berry D, Kashon ML, Simeonova PP: Potential in vitro effects of carbon nanotubes on human aortic endothelial cells.

    Toxicol Appl Pharmacol 2009, 236:319-328. PubMed Abstract | Publisher Full Text OpenURL

  35. Chaudhuri P, Harfouche R, Soni S, Hentschel DM, Sengupta S: Shape effect of carbon nanovectors on angiogenesis.

    ACS Nano 2010, 4:574-582. PubMed Abstract | Publisher Full Text OpenURL

  36. Prylutska SV, Burlaka AP, Prylutskyy YI, Ritter U, Scharff P: Pristine C(60) fullerenes inhibit the rate of tumor growth and metastasis.

    Exp Oncol 2011, 33:162-164. PubMed Abstract | Publisher Full Text OpenURL

  37. Mroz P, Tegos GP, Gali H, Wharton T, Sarna T, Hamblin MR: Photodynamic therapy with fullerenes.

    Photochem Photobiol Sci 2007, 6:1139-1149. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  38. Zogovic NS, Nikolic NS, Vranjes-Djuric SD, Harhaji LM, Vucicevic LM, Janjetovic KD, Misirkic MS, Todorovic-Markovic BM, Markovic ZM, Milonjic SK, Trajkovic VS: Opposite effects of nanocrystalline fullerene (C(60)) on tumour cell growth in vitro and in vivo and a possible role of immunosupression in the cancer-promoting activity of C(60).

    Biomaterials 2009, 30:6940-6946. PubMed Abstract | Publisher Full Text OpenURL

  39. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F: Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P.

    J Clin Invest 1994, 94:2036-2044. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  40. Maulik N: Reactive oxygen species drives myocardial angiogenesis?

    Antioxid Redox Signal 2006, 8:2161-2168. PubMed Abstract | Publisher Full Text OpenURL

  41. Harhaji L, Isakovic A, Raicevic N, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Markovic I, Trajkovic V: Multiple mechanisms underlying the anticancer action of nanocrystalline fullerene.

    Eur J Pharmacol 2007, 568:89-98. PubMed Abstract | Publisher Full Text OpenURL

  42. Sayes CM, Gobin AM, Ausman KD, Mendez J, West JL, Colvin VL: Nano-C60 cytotoxicity is due to lipid peroxidation.

    Biomaterials 2005, 26:7587-7595. PubMed Abstract | Publisher Full Text OpenURL

  43. Ostendorf T, Van Roeyen C, Westenfeld R, Gawlik A, Kitahara M, De Heer E, Kerjaschki D, Floege J, Ketteler M: Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors.

    J Am Soc Nephrol 2004, 15:2307-2319. PubMed Abstract | Publisher Full Text OpenURL

  44. Monti D, Moretti L, Salvioli S, Straface E, Malorni W, Pellicciari R, Schettini G, Bisaglia M, Pincelli C, Fumelli C, Bonafè M, Franceschi C: C60 carboxyfullerene exerts a protective activity against oxidative stress-induced apoptosis in human peripheral blood mononuclear cells.

    Biochem Biophys Res Commun 2000, 277:711-717. PubMed Abstract | Publisher Full Text OpenURL

  45. Isakovic A, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Mirkovic M, Dramicanin M, Harhaji L, Raicevic N, Nikolic Z, Trajkovic V: Distinct cytotoxic mechanism of pristine versus hydroxylated fullerene.

    Toxicol Sci 2006, 91:173-183. PubMed Abstract | Publisher Full Text OpenURL

  46. Meng H, Xing G, Sun B, Zhao F, Lei H, Li W, Song Y, Chen Z, Yuan H, Wang X, Long J, Chen C, Liang X, Zhang N, Chai Z, Zhao Y: Potent angiogenesis inhibition by the particulate form of fullerene derivatives.

    ACS Nano 2010, 4:2773-2783. PubMed Abstract | Publisher Full Text OpenURL